65 related articles for article (PubMed ID: 3402165)
1. Interferon responsiveness of natural killer cells in type I human diabetes.
Negishi K; Gupta S; Chandy KG; Waldeck N; Kershnar A; Buckingham B; Charles MA
Diabetes Res; 1988 Jan; 7(1):49-52. PubMed ID: 3402165
[TBL] [Abstract][Full Text] [Related]
2. Natural killer cell and islet killer cell activities in human type 1 diabetes.
Negishi K; Waldeck N; Chandy G; Buckingham B; Kershnar A; Fisher L; Gupta S; Charles AM
Exp Clin Endocrinol; 1987 Aug; 89(3):345-53. PubMed ID: 3311777
[TBL] [Abstract][Full Text] [Related]
3. In vitro generation of human activated lymphocyte killer cells: separate precursors and modes of generation of NK-like cells and "anomalous" killer cells.
Burns GF; Triglia T; Werkmeister JA
J Immunol; 1984 Sep; 133(3):1656-63. PubMed ID: 6611374
[TBL] [Abstract][Full Text] [Related]
4. Immune islet killing mechanisms associated with insulin-dependent diabetes: in vitro expression of cellular and antibody-mediated islet cell cytotoxicity in humans.
Charles MA; Suzuki M; Waldeck N; Dodson LE; Slater L; Ong K; Kershnar A; Buckingham B; Golden M
J Immunol; 1983 Mar; 130(3):1189-94. PubMed ID: 6337213
[TBL] [Abstract][Full Text] [Related]
5. Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanoma.
Hersey P; Coates A; Rallings M; Hall C; MacDonald M; Spurling A; Edwards A; McCarthy WH; Milton GW
J Biol Response Mod; 1986 Jun; 5(3):236-49. PubMed ID: 3487622
[TBL] [Abstract][Full Text] [Related]
6. [The functional activity and count of the natural killer cells in patients with recently diagnosed diabetes mellitus types I and II].
Salozhin KV; Sura VV; Nasonov EL; Korneeva MN; Smirnova OI
Ter Arkh; 1989; 61(10):104-6. PubMed ID: 2609254
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic and functional characterization of the circulating NK compartment in hairy cell leukaemia.
Foa R; Lauria F; Lusso P; Raspadori D; Fierro MT; Tazzari PL; Caudana L; Matera L
Clin Exp Immunol; 1986 May; 64(2):392-8. PubMed ID: 3742880
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.
Edwards BS; Hawkins MJ; Borden EC
Cancer Res; 1984 Jul; 44(7):3135-9. PubMed ID: 6586292
[TBL] [Abstract][Full Text] [Related]
9. Defective NK cell activity following thermal injury.
Klimpel GR; Herndon DN; Fons M; Albrecht T; Asuncion MT; Chin R; Stein MD
Clin Exp Immunol; 1986 Nov; 66(2):384-92. PubMed ID: 3493101
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of interferon-alpha 2 and interleukin-2 on natural killer cell activity in patients with acquired immune deficiency syndrome.
Reddy MM; Chinoy P; Grieco MH
J Biol Response Mod; 1984 Aug; 3(4):379-86. PubMed ID: 6332880
[TBL] [Abstract][Full Text] [Related]
11. Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons.
Brunda MJ; Rosenbaum D
Cancer Res; 1984 Feb; 44(2):597-601. PubMed ID: 6692364
[TBL] [Abstract][Full Text] [Related]
12. Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes.
Peters PM; Ortaldo JR; Shalaby MR; Svedersky LP; Nedwin GE; Bringman TS; Hass PE; Aggarwal BB; Herberman RB; Goeddel DV
J Immunol; 1986 Oct; 137(8):2592-8. PubMed ID: 3760569
[TBL] [Abstract][Full Text] [Related]
13. Systemic administration of human leukocyte interferon to melanoma patients. III. Increased helper:suppressor cell ratios in melanoma patients during interferon treatment.
Karavodin LM; Golub SH
Nat Immun Cell Growth Regul; 1983-1984; 3(4):193-202. PubMed ID: 6241293
[TBL] [Abstract][Full Text] [Related]
14. Natural killer activity in patients with acute viral hepatitis.
Chemello L; Mondelli M; Bortolotti F; Schiavon E; Pontisso P; Alberti A; Rondanelli EG; Realdi G
Clin Exp Immunol; 1986 Apr; 64(1):59-64. PubMed ID: 3089650
[TBL] [Abstract][Full Text] [Related]
15. Interferon enhanced natural killer function in Hodgkin's disease.
Levy S; Reins F; Aleksijevic A; Giron C; Oberling F; Mayer S; Lang JM
Nouv Rev Fr Hematol (1978); 1986; 28(5):323-5. PubMed ID: 3808943
[TBL] [Abstract][Full Text] [Related]
16. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of cell-mediated cytotoxicity at the single cell level. VI. Direct assessment of the cytotoxic potential of human peripheral blood non-lytic effector-target cell conjugates.
Bonavida B; Lebow LT; Bradley TP
J Immunol; 1984 Feb; 132(2):594-8. PubMed ID: 6606675
[TBL] [Abstract][Full Text] [Related]
18. Antibody- and interferon-dependent killer cells are part of the NK cell receptor positive subpopulation of human peripheral blood cells.
Ullberg M; Jondal M
Clin Exp Immunol; 1983 Jul; 53(1):101-8. PubMed ID: 6872324
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
Porrata LF; Inwards DJ; Lacy MQ; Markovic SN
Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790
[TBL] [Abstract][Full Text] [Related]
20. The "lazy" NK cells of Chediak-Higashi syndrome.
Targan SR; Oseas R
J Immunol; 1983 Jun; 130(6):2671-4. PubMed ID: 6602174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
